Key facts
- PsiThera’s last known valuation is $72.2M (Mar 2024).
- It has raised $97.5M; the latest was Early Stage VC ($47.5M) in Dec 2025.
- Notable investors include Johnson & Johnson JJDC, Samsara BioCapital, Lightstone Ventures, Eurofarma Ventures, Roivant Sciences — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for PsiThera
- ·The full record, as it builds
Funding rounds
No funding rounds for PsiThera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PsiThera
Developer of a physics-driven drug discovery platform intended to accelerate the design of new therapeutics. The company's platform utilises a combination of advanced computational physics, artificial intelligence, and machine learning, coupled with high-performance supercomputing infrastructure and in-house laboratory testing, enabling the life sciences industry to more accurately and discover and develop novel small molecules for previously intractable disease targets.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2022
- Employees
- 35
- Website
- psithera.com/
- Ownership
- Privately Held (backing)
PsiThera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PsiThera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PsiThera in its N-PORT filings yet. We sweep new filings monthly.